The estimated Net Worth of Darryl Wellinghoff is at least $40.7 Тысяча dollars as of 14 January 2020. Darryl Wellinghoff owns over 3,000 units of La Jolla Pharmaceutical Co stock worth over $40,710 and over the last 6 years Darryl sold LJPC stock worth over $0.
Darryl has made over 1 trades of the La Jolla Pharmaceutical Co stock since 2020, according to the Form 4 filled with the SEC. Most recently Darryl bought 3,000 units of LJPC stock worth $24,690 on 14 January 2020.
The largest trade Darryl's ever made was buying 3,000 units of La Jolla Pharmaceutical Co stock on 14 January 2020 worth over $24,690. On average, Darryl trades about 120 units every 0 days since 2019. As of 14 January 2020 Darryl still owns at least 6,545 units of La Jolla Pharmaceutical Co stock.
You can see the complete history of Darryl Wellinghoff stock trades at the bottom of the page.
Darryl's mailing address filed with the SEC is C/O LA JOLLA PHARMACEUTICAL COMPANY, 4550 TOWNE CENTRE COURT, SAN DIEGO, CA, 92121.
Over the last 21 years, insiders at La Jolla Pharmaceutical Co have traded over $13,460,170 worth of La Jolla Pharmaceutical Co stock and bought 11,640,515 units worth $137,250,039 . The most active insiders traders include Advisors Llcperceptive Life..., James N Topper и Woodlands Health Ventures F.... On average, La Jolla Pharmaceutical Co executives and independent directors trade stock every 63 days with the average trade being worth of $1,249,971. The most recent stock trade was executed by Craig A Johnson on 8 July 2022, trading 12,000 units of LJPC stock currently worth $47,160.
La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.
La Jolla Pharmaceutical Co executives and other stock owners filed with the SEC include: